The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct
In a multicentre phase 3 trial, researchers at the MHH have demonstrated the efficacy and safety of the drug Bulevirtide, which prevents Hepatitis D viruses from entering the liver.
Antibiotics affect the composition and dynamics of the gut microbiome. Treatment with antibiotics not only leads to a loss of biodiversity of microorganisms, but also often favours the selection of
It was previously believed that herpesviruses use certain body cells to replicate and other body cells to remain dormant, that is to remain inactive for a longer period of time. This dogma is now
Researchers at the University Medical Center Hamburg-Eppendorf have demonstrated cross-reactive immune responses to another SARS-CoV-2 protein besides the spike protein. The research team found a
Colistin is a last-line reserve antibiotic for the treatment of infections caused by extremely multidrug-resistant (XDR) Gram-negative bacteria. The recent emergence and global spread of the mobile
Dr. Victoria Ingham from Heidelberg University Hospital and the German Center for Infection Research (DZIF) is investigating the potential dual effect of a new insecticide for mosquito nets. The
Infections with the bacterium Clostridioides difficile (C. difficile for short) frequently recur due to permanent stages remaining in the intestine. A drug that also effectively combats the permanent
The pathogenHelicobacter pylori, which is responsible for highly prevalent diseases such as gastric ulcers or cancer, has a weak spot that could be used to produce new drugs. This was discovered by a
African and European partners join forces to enable the World Health Organisation’s (WHO) “Road Map for Neglected Tropical Diseases” (NTDs) and reduce the burden of disease associated with worm